<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="64324">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02268526</url>
  </required_header>
  <id_info>
    <org_study_id>CCSJ148X2201</org_study_id>
    <nct_id>NCT02268526</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of CSJ148 Compared to Placebo to Prevent Human Cytomegalovirus (HCMV) Replication in Stem Cell Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to test if CSJ148 can prevent HCMV replication after stem cell
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is randomized, double-blinded, and placebo-controlled. 80 Patients will be
      enrolled and randomized to CSJ148 and placebo in a ratio of 3:1. Patients undergoing stem
      cell transplantation will be enrolled into the study. The study will consist of a screening
      period, a baseline visit, approximately 3-month treatment exposure period, an end-of-therapy
      visit, a follow-up period, and a study completion evaluation approximately 3.5 months after
      the last dose of study drug is administered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2, 2015</start_date>
  <completion_date type="Actual">December 7, 2016</completion_date>
  <primary_completion_date type="Actual">December 7, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who require preemptive HCMV therapy</measure>
    <time_frame>99 days</time_frame>
    <description>Outcome is based on HCMV viral load</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>99 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to initiation of preemptive HCMV therapy</measure>
    <time_frame>99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of times that preemptive HCMV therapy is required</measure>
    <time_frame>99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants developing HCMV disease</measure>
    <time_frame>99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve during the dosing interval (AUCtau)</measure>
    <time_frame>99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration during the dosing interval (Cmax)</measure>
    <time_frame>99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough serum concentration (Ctrough)</measure>
    <time_frame>99 days</time_frame>
    <description>Prior to the next dose administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>HCMV</condition>
  <arm_group>
    <arm_group_label>CSJ148</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSJ148</intervention_name>
    <arm_group_label>CSJ148</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients at least 18 years of age scheduled to undergo allogeneic
             bone marrow, peripheral blood stem cell, or cord blood transplantation and begin
             conditioning chemotherapy within 24-48 hours of planned dosing day.

          -  Subject seropositive for HCMV before transplantation; donor can be seropositive or
             seronegative for HCMV (donor positive/recipient positive or donor negative/recipient
             positive).

        Exclusion Criteria:

          -  Have had HCMV-related organ disease within 6 months prior to enrollment.

          -  Detectable HCMV infection (positive pp65 antigenemia or plasma HCMV DNA polymerase
             chain reaction (PCR) assays prior to enrollment

          -  Received any of the following within 30 days prior to enrollment: ganciclovir,
             valganciclovir, foscarnet, cidofovir, acyclovir (&gt;25 mg/kg/day IV), valacyclovir (&gt;3
             gm/day oral), famciclovir (&gt;1500 mg/day oral), HCMV immune globulin, immune globulin
             (&gt;500 mg/kg), or any other medication with anti-HCMV activity.

          -  Require mechanical ventilation within 7 days prior to enrollment.

          -  Received any vasopressors or other agents for hemodynamic support within 7 days prior
             to enrollment.

          -  Impaired renal function requiring dialysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beach Grove</city>
        <state>Indiana</state>
        <zip>46107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lin-Kou</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 13, 2017</lastchanged_date>
  <firstreceived_date>August 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety, efficacy, pharmacokinetics, CSJ148, HCMV, HCMV viral load,</keyword>
  <keyword>immunogenicity</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
